非小细胞肺癌的分子靶向治疗 2014 年年度更新。
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
机构信息
*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.
出版信息
J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.
There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.
在过去的几年中，人们对非小细胞肺癌（NSCLC）的生物学和治疗有了重大的认识进展。许多针对分子靶点的药物已经应用于晚期 NSCLC 患者的临床治疗或正在开发中。我们开始了解在患有癌基因依赖型 NSCLC 的患者中，在接触酪氨酸激酶抑制剂后获得性耐药的机制。下一代测序技术的出现使我们能够全面研究肺癌中的基因组改变。最后，免疫检查点抑制剂的早期结果非常令人鼓舞。本文综述了癌症基因组学、靶向治疗和免疫治疗领域的最新进展。
Zotero 插件